Combining chemotherapy with an immune-blocking drug could stop cancer growing back

14 Aug 2015

1

Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people, according to scientisits from the University of Sheffield.

Cancer Research UK-funded scientists from the University of Sheffield, found that the cancer-killing action of chemotherapy can trigger a swarm of wound-healing, white blood cells to cluster around blood vessels in a treatment-hit tumour.

These cells – called M2 macrophages - repair tissue damage and build new blood vessels, a process that sometimes helps the tumour to grow again after treatment. (Macrophages are a type of white blood cells and are often found in two forms in the body: M1 macrophages, which protect against infection and can work to destroy tumours, and M2 macrophages which promote wound-healing and have been linked to tumour growth and spread. Scientists in this research targeted and blocked the accumulation of M2 cells in tumours after chemotherapy.)

But by treating mice with cancer with a drug ( the scientists used Plerixafor during this research) that stops these repair cells from working, the researchers markedly reduced the speed at which tumours grew back after chemotherapy.

Lead scientist on the study, Professor Claire Lewis at the University of Sheffield's Department of Oncology, says, "Scientists already knew that the body's drive to heal itself can sometimes backfire when the immune system reacts to tissue damage.

"Our research shows that treating tumours with chemotherapy can activate this part of the immune system, and this then helps tumours re-grow afterwards, " says Dr Russell Hughes from the team that made the discovery.
 
''But combining chemotherapy with a drug that switches off this part of the body's repair system, slowed the growth of tumours after chemotherapy. This could be particularly important for patients who can't have surgery and, therefore, need chemotherapy to help them live for as long as possible.''

Clinical trials of patients are needed to confirm these early findings to see if the drug – already used in patients for other reasons, such as bone marrow transplants - could help cancer patients after chemotherapy.

Dr Áine McCarthy, Science Communications Officer at Cancer Research UK, says, ''Chemotherapy is a cornerstone cancer treatment that saves thousands of lives, but sometimes tumours come back, reducing patients' chances of survival. We don't understand all the reasons why tumours do come back, but this study sheds new light on the role of the immune system in causing tumours to grow again and, importantly, identifies a drug that could block this happening if given at the same time as chemotherapy.

''But this is early research carried out in mice and more work is needed to see if blocking M2 macrophages can also slow down tumour re-growth in patients.''

Latest articles

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

Toyota set for third straight quarterly profit drop as costs and tariffs weigh

Toyota set for third straight quarterly profit drop as costs and tariffs weigh